

**For Immediate Release**

## **DIMERIX 2018 ANNUAL GENERAL MEETING DIAL-IN DETAILS**

MELBOURNE, Australia, 25 October 2018: Dimerix Limited (ASX: DXB), a clinical stage biotechnology company is pleased to invite shareholders to participate in the 2018 Annual General Meeting (AGM) via a dial-in facility, to be held in Perth on Tuesday 30<sup>th</sup> October at 10:00 am WST (1:00 pm AEST / Sydney time).

During the AGM, Dr James Williams, Executive Chairman, will chair the meeting, including a short presentation by Dr Nina Webster, Chief Executive Officer and Managing Director.

Shareholders are invited to submit general questions ahead of the AGM to [glen.zurcher@irdepartment.com.au](mailto:glen.zurcher@irdepartment.com.au).

The AGM presentation will be lodged on the morning of the AGM.

### **Date and time**

Tuesday 30<sup>th</sup> October at 10:00 am WST (1:00 pm AEST / Sydney time)

### **Dial-in details**

Australia	1800 123 296
United States	1855 293 1544

**Conference ID**            **3199415**

### **Shareholders attending in person**

Stantons, Level 2, 1 Walker Avenue, West Perth WA 6005

For further information, please visit our website at [www.dimerix.com](http://www.dimerix.com) or contact the individuals outlined below.

—END—

### **At the Company**

Dr Nina Webster  
Dimerix Limited  
Chief Executive Officer  
E: [investor@dimerix.com](mailto:investor@dimerix.com)

### **Investor Relations**

Glen Zurcher  
IR Department  
Account Director  
Tel: +61 420 249 299  
E: [glen.zurcher@irdepartment.com.au](mailto:glen.zurcher@irdepartment.com.au)

### **About Dimerix Bioscience Pty Ltd**

Dimerix Limited's (ASX: DXB) wholly owned subsidiary Dimerix Bioscience Pty Ltd is a dynamic, clinical-stage drug development company, developing and commercialising patient-preferred and patent protected pharmaceutical products for global markets. Dimerix is currently developing its product DMX-200 for both Diabetic Kidney Disease and Focal Segmental Glomerulosclerosis (FSGS). DMX-200 was identified using Dimerix' proprietary assay, termed Receptor-Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities.

For more information see [www.dimerix.com](http://www.dimerix.com)